Traders should monitor for potential downward pressure on the stock, especially if additional selling follows. The coordinated exit by CFO and CMO raises questions about internal confidence, particularly in a biopharma context where clinical progress is key. Absent positive news, this could signal overvaluation or upcoming risk.
IRON drugs
IRON drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $68.46entry
- T+1 · 7mo ago +2.95%α +1.74% · $70.48
- T+5 · 7mo ago +4.31%α +1.01% · $71.41
- T+20 · 6mo ago +1.12%α −6.60% · $69.23
- T+60 · 4mo ago +16.94%α +8.02% · $80.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite executives at Disc Medicine, Inc. (IRON) sold shares worth $694K in the past week, including CFO Jean M. Franchi and CMO William Jacob Savage. The sales were open-market transactions, representing a coordinated insider sell-off by top leadership.
Key Financial Metrics
Key Facts
- CFO Jean M. Franchi sold 6,657 shares for $460,834 in two transactions on April 13 and 14, 2026.
- CMO William Jacob Savage sold 3,531 shares for $233,473 on April 13, 2026.
- Total insider sales in the past 7 days amount to $694,307 in open-market transactions.
- All transactions were 'S' (open-market sale) codes, indicating deliberate divestment.
- Total value represents ~0.026% of the $2.7B market cap, modest in size but significant given concentration among C-suite executives.
Financial Impact
$694K in open-market share sales by two C-suite executives
Risk Factors
- Perception of insider pessimism ahead of clinical data or regulatory decisions
- Potential for follow-on selling by other insiders
- Increased scrutiny from retail and institutional investors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IRON-1776287155695 |
Track record
43 reports on IRON
7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers